HomePage

Flamel Technologies SA is a specialty pharmaceutical company with a long history of expertise in drug delivery. The acquisition of Éclat Pharmaceuticals LLC has created a more vertically integrated company, benefiting from greater development and commercial expertise, best in class drug delivery platforms and potential value creating catalysts.

Drug Delivery Platforms

  • Micropump®

    Controlled release of oral drugs.

    Read more

  • LiquiTime®

    Controlled release oral liquid drugs.

    Read more

  • Trigger Lock

    Tamper-resistant controlled release formulations of narcotics and other drugs prone to abuse.

    Read more

  • Medusa

    Controlled release of injected biologics and small molecules drugs.

    Read more

Products

Flamel Technologies currently markets Bloxiverz and Vazculep (FDA-approved products), and develops internally products using the Unapproved Marketed Drug strategy and products based on its drug delivery platforms, and products with partners.

  • Bloxiverz website
  • Vazculep website

Investors

As a publicly-held company, Flamel Technologies strives to use its technologies to create extraordinary shareholder value.